PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model

• Published in: BMC cancer Vol. 18; no. 1; pp. 669 - 7
• Main Authors: Li, Yuan, Du, Yang, Sun, Ting, Xue, Huadan, Jin, Zhengyu, Tian, Jie
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 19.06.2018; BioMed Central; BMC
• Subjects: Acids; Angiogenesis; Animals; Antibodies, Monoclonal - administration & dosage; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antitumor activity; Bioluminescence; Breast cancer; Cancer therapies; Cancer treatment; Care and treatment; Checkpoint inhibitior; Chemotherapy; Disease Models, Animal; Drug dosages; Female; Flow cytometry; Health aspects; Immune system; Immunoglobulins; Immunomodulation; Immunotherapy; Ligands; Lung cancer; Lymphocytes T; Mammary Neoplasms, Experimental - pathology; Medical prognosis; Metastasis; Mice; Mice, Inbred BALB C; Monoclonal antibodies; PD-1; PD-1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Prostate cancer; Stem cells; Substance abuse treatment; Therapy; Toxicity; Tumor cells; Tumors; Zoledronic acid; Zoledronic Acid - administration & dosage; United States > US; Zoledronic acid; Therapy; Breast cancer; Checkpoint inhibitior; PD-1

Blockade of PD-1 receptor may provide proof of concepts for the activity of an immune-modulation approach for the treatment of breast cancer (BC). Zoledronic acid (ZA) has been proven to inhibit angiogenesis, invasion, and adhesion of tumor cells. The aim of this study was to investigate the potenti...